Diagnostics

A new partnership brings a high-speed digital pathology scanner to the U.S. for the first time, promising to revolutionize diagnostic speed and accuracy.

Over 140 health groups warn the EPA's 'flawed' fluoride review could reverse decades of public health gains, sparking a surge in childhood tooth decay.

Colorectal cancer is the #1 cancer killer for adults under 50. A new study reveals a shocking awareness gap that is fueling this growing public health crisis.

European biotech leader Hifas da Terra launches in the US, aiming to disrupt the mushroom supplement industry with its unique focus on clinical trials.

Fulgent Genetics reports revenue growth but faces a pivotal year with a major customer loss, betting its future on strategic acquisitions and a promising drug pipeline.

With Google's Rick Osterloh on its board, Dexcom signals a major push beyond diabetes into AI-powered wellness and the consumer wearables market.

The diagnostics firm topped revenue forecasts with explosive growth in core tests, navigating a net loss with a strategic pivot into new markets.

One in 10 Canadians has kidney disease, often with no symptoms. Experts urge immediate action as this silent crisis strains lives and our healthcare system.

With TGA approval, Optellum's AI platform arrives to help tackle Australia's low lung cancer survival rates by enabling earlier, more accurate detection.

With millions of Canadians suffering from dry eye, a new program combines advanced tech like IPL with personalized plans to offer hope and accessible relief.

A new skincare brand is skipping mass marketing, embedding its products with veterans, skiers, and melanoma researchers to redefine sun protection.

Spectral Medical shifts its FDA submission for a breakthrough sepsis device, a strategic move that could strengthen its case but delays a potential lifeline.

With a key FDA decision looming and pivotal data on a second therapy imminent, Viridian is poised to reshape the multi-billion dollar Thyroid Eye Disease market.

A new collaboration is betting on tiny natural particles to deliver a gene-editing cure for a devastating neurological disorder, bypassing a key medical hurdle.

A novel mouse model with human immune receptors promises to slash the high failure rate of antibody therapies, accelerating life-saving treatments.

A nonprofit is investing millions in a novel program to fast-track academic breakthroughs for neurological diseases from the lab to patients.

A new partnership brings AI voice analysis to home caregiving, promising proactive support for seniors but raising new questions about privacy in our living rooms.

IMO Health integrates a global rare disease database into EHRs, promising to shorten diagnosis times and accelerate vital research for millions.

Amid a surge in MedTech M&A, Piper Sandler appoints 25-year veteran Aamer Naseer to steer its life sciences outsourcing and B2B technology groups.

Curanex Pharmaceuticals hits a key manufacturing milestone for Phyto-N, a botanical drug with a 30-year history, advancing its quest for FDA approval.